CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 179 enrolled
Drug / intervention
IQOS +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03364751
NCT03364751N/ACompleted
CompareCT.gov

A 6-month Randomized, Controlled, Open-label, 2-arm Parallel Group, Multicenter Study to Evaluate the Effect of Switching From Cigarette Smoking to the Use of IQOS in Smokers With Generalized Chronic Periodontitis on the Response to Mechanical Periodontal Treatment and Oral Health Status.

Philip Morris Products S.A.·interventional·Posted Dec 7, 2017·Updated Jan 30, 2023

In Brief

A clinical study evaluating IQOS and Cigarette for Periodontal Diseases and 5 related conditions. Completed, enrolled 179 participants across 26 sites.

Detailed Summary

The purpose of this study was to demonstrate in patients with generalized chronic periodontitis that switching from cigarette smoking to using IQOS improves the response to periodontal therapy and the overall oral health status compared to continuing cigarette smoking. Note: "IQOS" is the Tobacco Heating System (THS) with Marlboro Heatsticks, marketed in Japan under the brand name IQOS

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeriodontal Diseases, Chronic Periodontitis, Periodontal Pocket, Tooth Mobility, Gingival Diseases, Smoking, Cigarette
CountriesJapan
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedDec 7, 2017
Enrollment StartNov 7, 2017
Primary CompletionDec 21, 2018
Study CompletionJun 12, 2019
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 8.6 years ago

Interventions

IQOSother

Patients will switch from cigarette smoking to ad libitum IQOS use.

Cigaretteother

Patients will continue to smoke cigarettes ad libitum.